51˶

CardioBreak: Valve-in-Valve, Brilinta Crush, Denervation Revamp

— Recent developments of interest in cardiovascular medicine.

Last Updated April 7, 2015
MedpageToday

The FDA expanded CoreValve's indication to to replace tissue aortic prostheses in patients at high or extreme risk from open surgery.

It also approved a new administration option for ticagrelor (Brilinta). For patients who can't swallow the tablets whole, the blood thinner can be to be swallowed or given via nasogastric tube, AstraZeneca announced.

Boehringer Ingelheim is seeking to round out the indications for dabigatran (Pradaxa) with an in hip replacement surgery, which the FDA has now accepted for review.

A randomized, sham-controlled trial of showed no impact on ambulatory blood pressure after 6 months, in keeping with failure of the SYMPLICITY HTN-3 trial in more severe resistant hypertension.

Meanwhile, Medtronic is pressing forward with its plans to reinvigorate renal denervation with a after its next-gen catheter, aimed at addressing possible confounding factors that led to SYMPLICITY HTN-3's failure. Two sham-controlled trials will target moderate- to high-risk hypertension this time.

", particularly frequent use, was associated with reduced risk of total and ischemic stroke mortality among Japanese people with lower intake of fruits and vegetables," a study observed.

Do baseline blood tests for everything? Celebrity billionaire Mark Cuban "should take the cigar out of his mouth and ," CardioBrief's Larry Husten says.

A useful guide to thrombophilia testing for patients can be found , from 's Stephan Moll, MD, and a colleague.

A new set of ICD 10 codes for each level of NIH Stroke Scale score, allowing for CMS to , will go live in fall 2016, which the American Stroke Association Stroke Council called a "major accomplishment."

CardioBreak is a guide to what's new and interesting on the Web for cardiologists and other healthcare professionals with an interest in cardiovascular disease, powered by the 51˶ community. Got a tip? Send it to us: c.phend@medpagetoday.com.